Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 10/20 | 0.56 |
| ▸ | FNTB | P49356 | 10/20 | 0.56 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7208658 | 0.80 | FNTA (0.56) | FNTAFNTBPGGT1BCNR1CNR2 | |
| SCHEMBL7209530 | 0.80 | FNTA (0.53) | FNTAFNTBPGGT1BCA12CA9 | |
| SCHEMBL4428705 | 0.79 | FNTA (0.56) | FNTAFNTBPGGT1BMAPT | |
| SCHEMBL7207687 | 0.78 | POLB (0.39) | FNTAFNTBPGGT1BCNR1CNR2 | |
| SCHEMBL4432018 | 0.74 | FNTA (0.51) | FNTAFNTBPGGT1BCNR1CNR2 | |
| SCHEMBL4426318 | 0.74 | FNTA (0.49) | FNTAFNTBPGGT1BCA12CA9 | |
| SCHEMBL7209481 | 0.74 | FNTA (0.59) | FNTAFNTBPGGT1BCA12CA9 | |
| SCHEMBL7210122 | 0.72 | FNTA (0.54) | FNTAFNTBPGGT1BCNR1 | |
| SCHEMBL30419724 | 0.72 | FNTA (0.56) | FNTAFNTBSMN1; SMN2 | |
| SCHEMBL1538260 | 0.72 | FNTA (0.56) | FNTAFNTBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458720-B1 | 1,8-ANNELATED QUINOLINE DERIVATIVES SUBSTITUTED WITH CARBON-LINKED TRIAZOLES AS FARNESYL TRANSFERASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-03-18 | — | — | EP | disclosed |
| US-7408063-B2 | 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-05 | — | — | US | disclosed |
| US-20050176702-A1 | 1,8-Annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176702-A1 | 1,8-Annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors | FNTA, FNTB, ACAT2 | FNTA 1/4885FNTB 2/4885PGGT1B 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.